Hypersensitivity: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
(→‎Type 1 - immediate (or atopic, or anaphylactic): removed Penicillin & Cephalosporin as these are examples of causes; not examples of manifestations)
imported>Robert Badgett
Line 58: Line 58:
{{seealso|Cell mediated immunity}}
{{seealso|Cell mediated immunity}}


Type 4 hypersensitivity is often called delayed type as the reaction takes two to three days to develop. Unlike the other types, it is not antibody mediated but rather is a type of cell-mediated response.
Type 4 hypersensitivity is often called delayed type as the reaction takes two to three days to develop. Unlike the other types of hypersensitivity, it is mediated by T-cells rather than B-cells.


CD8+ [[cytotoxic T cell]]s and CD4+ [[helper T cell]]s recognise antigen in a complex with either type 1 or 2 [[major histocompatibility complex]]. The antigen-presenting cells in this case are macrophages which secrete [[IL-12]], which stimulates the proliferation of further CD4+ T cells. CD4+ T cells secrete [[IL-2]] and [[interferon]] gamma, further inducing the release of other Type 1 cytokines, thus mediating the immune response. Activated CD8+ T cells destroy target cells on contact while activated macrophages produce [[hydrolytic enzyme|hydrolytic]] [[enzyme]]s and, on presentation with certain intracellular pathogens, transform into multinucleated [[giant cell]]s.
Type 4 reactions can be subdivided by the specific type of T-cell response that occurs when macrophages present antigen in a complex with either type 1 or 2 [[major histocompatibility complex]].<ref name="pmid14568857">{{cite journal |author=Pichler WJ |title=Delayed drug hypersensitivity reactions |journal=Ann. Intern. Med. |volume=139 |issue=8 |pages=683–93 |year=2003 |pmid=14568857 |doi=|url=http://www.annals.org/cgi/content/full/139/8/683}}</ref>
* Type 4a: T-helper (CD4<sup>+</sup>) Type 1 (T<sub>H</sub>1) T cells secrete [[interferon]]-gamma which activates macrophages to produce complement-fixing antibody isotypes.
* Type 4b: T-helper (CD4<sup>+</sup>) Type 2 (T<sub>H</sub>2) T cells secrete the cytokines interleukin-4 and interleukin-5, which promote B-cell production of IgE and IgG4, macrophage deactivation, and mast-cell and eosinophil responses.
* Type 4c: Cytolytic T-cells (CD8<sup>+</sup>) (CTLs or T<sub>C</sub> cells) T cells secrete the cytokines performin and granzyme B.
* Type 4d: T-cells produce interleukin-8 which activates neutrophils.


Some clinical examples:
Some clinical examples:
*[[Contact dermatitis]] ([[Toxicodendron radicans|poison ivy]] rash, for example)
*[[Atopic dermatitis]] (eczema)
*[[Atopic dermatitis]] (eczema)
*[[Temporal arteritis]]
*[[Contact dermatitis]]. An example is the [[Toxicodendron radicans|poison ivy]] rash, which is predominantly a Type 4a reaction.
*Symptoms of [[leprosy]]
*Symptoms of [[tuberculosis]]
*[[Mantoux test]]
*[[Coeliac disease]]
*[[Coeliac disease]]
*[[Chronic transplant rejection]]
*[[Chronic transplant rejection]]
*[[Leprosy]]
*[[Mantoux test]]
*[[Temporal arteritis]]
*[[Tuberculosis]]


===Type 5 - stimulatory ===
===Type 5 - stimulatory ===

Revision as of 02:48, 16 January 2008

This article is developing and not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Hypersensitivity is defined as "altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.."[1]

Classification

The four-group classification was proposed in 1963.[2]

Type 1 - immediate (or atopic, or anaphylactic)

Type 1 hypersensitivity is an allergic reaction provoked by reexposure to a specific type of antigen referred to as an allergen. Exposure may be by ingestion, inhalation, injection, or direct contact. The difference between a normal immune response and a type I hypersensitive response is that plasma cells secrete IgE. This class of antibodies binds to Fc receptors on the surface of tissue mast cells and blood basophils. Mast cells and basophils coated by IgE are "sensitized." Later exposure to the same allergen, cross-links the bound IgE on sensitized cells resulting in degranulation and the secretion of pharmacologically active mediators such as histamine, leukotriene, and prostaglandin that act on the surrounding tissues. The principal effects of these products are vasodilation and smooth-muscle contraction.

The reaction may be either local or systemic. Symptoms vary from mild irritation to sudden death from anaphylactic shock. Treatment usually involves epinephrine, antihistamines, and corticosteroids.

Some examples:

Type 2 - antibody-dependent

In type 2 hypersensitivity, the antibodies produced by the immune response bind to antigens on the patient's own cell surfaces. The antigens recognized in this way may either be intrinsic ("self" antigen, innately part of the patient's cells) or extrinsic (absorbed onto the cells during exposure to some foreign antigen, possibly as part of infection with a pathogen). These cells are recognised by macrophages or dendritic cells which act as antigen presenting cells, this causes a B cell response where antibodies are produced against the foreign antigen.

An example here is the reaction to penicillin where the drug can bind to red blood cells causing them to be recognised as different, B cell proliferation will take place and antibodies to the drug are produced. IgG and IgM antibodies bind to these antigens to form complexes that activate the classical pathway of complement activation for eliminating cells presenting foreign antigens (which are usually, but not in this case, pathogens). That is, mediators of acute inflammation are generated at the site and membrane attack complexes cause cell lysis and death. The reaction takes hours to a day.

Another form of type 2 hypersensitivity is called antibody-dependent cell-mediated cytotoxicity (ADCC). Here, cells exhibiting the foreign antigen are tagged with antibodies (IgG or IgM). These tagged cells are then recognised by natural killer (NK) cells and macrophages (recognised via IgG bound (via the Fc region) to the effector cell surface receptor, CD16 (FcγRIII)), which in turn kill these tagged cells.

Some examples:

Type 3 - immune complex diseases

Type 3 hypersensitivity occurs when antigens and antibodies are present in roughly equal amounts, causing extensive cross-linking. Large immune complexes that cannot be cleared are deposited in vessel walls and induce an inflammatory response. The reaction can take hours, days, or even weeks to develop.

Some clinical examples:

Type 4 - cell-mediated (delayed-type hypersensitivity, DTH)

See also: Cell mediated immunity

Type 4 hypersensitivity is often called delayed type as the reaction takes two to three days to develop. Unlike the other types of hypersensitivity, it is mediated by T-cells rather than B-cells.

Type 4 reactions can be subdivided by the specific type of T-cell response that occurs when macrophages present antigen in a complex with either type 1 or 2 major histocompatibility complex.[3]

  • Type 4a: T-helper (CD4+) Type 1 (TH1) T cells secrete interferon-gamma which activates macrophages to produce complement-fixing antibody isotypes.
  • Type 4b: T-helper (CD4+) Type 2 (TH2) T cells secrete the cytokines interleukin-4 and interleukin-5, which promote B-cell production of IgE and IgG4, macrophage deactivation, and mast-cell and eosinophil responses.
  • Type 4c: Cytolytic T-cells (CD8+) (CTLs or TC cells) T cells secrete the cytokines performin and granzyme B.
  • Type 4d: T-cells produce interleukin-8 which activates neutrophils.

Some clinical examples:

Type 5 - stimulatory

This is an additional type that is sometimes (often in Britain) used as a distinction from Type 2.[4]

Instead of binding to cell surface components, the antibodies recognize and bind to the cell surface receptors, which either prevents the intended ligand binding with the receptor or mimics the effects of the ligand, thus impairing cell signalling.

Some clinical examples:

References

  1. National Library of Medicine. Hypersensitivity. Retrieved on 2007-12-31.
  2. Gell PGH, Coombs RRA, eds. Clinical Aspects of Immunology. 1st ed. Oxford, England: Blackwell; 1963.
  3. Pichler WJ (2003). "Delayed drug hypersensitivity reactions". Ann. Intern. Med. 139 (8): 683–93. PMID 14568857[e]
  4. Rajan TV (2003). "The Gell-Coombs classification of hypersensitivity reactions: a re-interpretation". Trends Immunol. 24 (7): 376–9. PMID 12860528[e]